Cullinan Therapeutics Statistics
Total Valuation
CGEM has a market cap or net worth of $476.29 million. The enterprise value is $79.47 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CGEM has 58.51 million shares outstanding. The number of shares has increased by 29.41% in one year.
| Current Share Class | 58.51M |
| Shares Outstanding | 58.51M |
| Shares Change (YoY) | +29.41% |
| Shares Change (QoQ) | +0.42% |
| Owned by Insiders (%) | 4.02% |
| Owned by Institutions (%) | 83.39% |
| Float | 38.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.53, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.53 |
| Quick Ratio | 13.23 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.10% and return on invested capital (ROIC) is -23.44%.
| Return on Equity (ROE) | -32.10% |
| Return on Assets (ROA) | -22.26% |
| Return on Invested Capital (ROIC) | -23.44% |
| Return on Capital Employed (ROCE) | -33.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.51M |
| Employee Count | 111 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CGEM has paid $117,000 in taxes.
| Income Tax | 117,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.91% in the last 52 weeks. The beta is -0.05, so CGEM's price volatility has been lower than the market average.
| Beta (5Y) | -0.05 |
| 52-Week Price Change | -56.91% |
| 50-Day Moving Average | 8.34 |
| 200-Day Moving Average | 13.36 |
| Relative Strength Index (RSI) | 50.98 |
| Average Volume (20 Days) | 530,448 |
Short Selling Information
The latest short interest is 7.99 million, so 13.66% of the outstanding shares have been sold short.
| Short Interest | 7.99M |
| Short Previous Month | 8.53M |
| Short % of Shares Out | 13.66% |
| Short % of Float | 20.50% |
| Short Ratio (days to cover) | 16.38 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -196.92M |
| Pretax Income | -156.28M |
| Net Income | -167.38M |
| EBITDA | -196.61M |
| EBIT | -196.92M |
| Earnings Per Share (EPS) | -$3.11 |
Full Income StatementBalance Sheet
The company has $398.98 million in cash and $2.15 million in debt, giving a net cash position of $396.83 million or $6.78 per share.
| Cash & Cash Equivalents | 398.98M |
| Total Debt | 2.15M |
| Net Cash | 396.83M |
| Net Cash Per Share | $6.78 |
| Equity (Book Value) | 590.33M |
| Book Value Per Share | 10.09 |
| Working Capital | 384.02M |
Full Balance SheetCash Flow
| Operating Cash Flow | -145.30M |
| Capital Expenditures | n/a |
| Free Cash Flow | -145.30M |
| FCF Per Share | -$2.48 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |